Display options
Cite
Padilla J, Jenkins NT, Thorne PK, et al. Differential regulation of adipose tissue and vascular inflammatory gene expression by chronic systemic inhibition of NOS in lean and obese rats. Physiol Rep. 2014;2(2):e00225doi: 10.1002/phy2.225.
Padilla, J., Jenkins, N. T., Thorne, P. K., Lansford, K. A., Fleming, N. J., Bayless, D. S., Sheldon, R. D., Rector, R. S., & Laughlin, M. H. (2014). Differential regulation of adipose tissue and vascular inflammatory gene expression by chronic systemic inhibition of NOS in lean and obese rats. Physiological reports, 2(2), e00225. https://doi.org/10.1002/phy2.225
Padilla, Jaume, et al. "Differential regulation of adipose tissue and vascular inflammatory gene expression by chronic systemic inhibition of NOS in lean and obese rats." Physiological reports vol. 2,2 (2014): e00225. doi: https://doi.org/10.1002/phy2.225
Padilla J, Jenkins NT, Thorne PK, Lansford KA, Fleming NJ, Bayless DS, Sheldon RD, Rector RS, Laughlin MH. Differential regulation of adipose tissue and vascular inflammatory gene expression by chronic systemic inhibition of NOS in lean and obese rats. Physiol Rep. 2014 Feb 07;2(2):e00225. doi: 10.1002/phy2.225. eCollection 2014 Feb 01. PMID: 24744894; PMCID: PMC3966247.
Copy Download .nbib Format: NLM
Share it on

Physiol Rep. 2014 Feb 07;2(2):e00225. doi: 10.1002/phy2.225. eCollection 2014 Feb 01.

Differential regulation of adipose tissue and vascular inflammatory gene expression by chronic systemic inhibition of NOS in lean and obese rats.

Physiological reports

Jaume Padilla, Nathan T Jenkins, Pamela K Thorne, Kasey A Lansford, Nicholas J Fleming, David S Bayless, Ryan D Sheldon, R Scott Rector, M Harold Laughlin

Affiliations

  1. Nutrition and Exercise Physiology, University of Missouri, Columbia, Missouri ; Child Health, University of Missouri, Columbia, Missouri ; Dalton Cardiovascular Research Center, University of Missouri, Columbia, Missouri.
  2. Kinesiology, University of Georgia, Athens, Georgia.
  3. Biomedical Sciences, University of Missouri, Columbia, Missouri.
  4. Biomedical Sciences, University of Missouri, Columbia, Missouri ; Medical Pharmacology and Physiology, University of Missouri, Columbia, Missouri.
  5. Nutrition and Exercise Physiology, University of Missouri, Columbia, Missouri ; Harry S Truman Memorial VA Medical Center, Columbia, Missouri.
  6. Nutrition and Exercise Physiology, University of Missouri, Columbia, Missouri ; Harry S Truman Memorial VA Medical Center, Columbia, Missouri ; Internal Medicine-Division of Gastroenterology and Hepatology, University of Missouri, Columbia, Missouri.
  7. Dalton Cardiovascular Research Center, University of Missouri, Columbia, Missouri ; Biomedical Sciences, University of Missouri, Columbia, Missouri ; Medical Pharmacology and Physiology, University of Missouri, Columbia, Missouri.

PMID: 24744894 PMCID: PMC3966247 DOI: 10.1002/phy2.225

Abstract

We tested the hypothesis that a decrease in bioavailability of nitric oxide (NO) would result in increased adipose tissue (AT) inflammation. In particular, we utilized the obese Otsuka Long Evans Tokushima Fatty rat model (n = 20) and lean Long Evans Tokushima Otsuka counterparts (n = 20) to determine the extent to which chronic inhibition of NO synthase (NOS) with N (ω) -nitro-l-arginine methyl ester (L-NAME) treatment (for 4 weeks) upregulates expression of inflammatory genes and markers of immune cell infiltration in retroperitoneal white AT, subscapular brown AT, periaortic AT as well as in its contiguous aorta free of perivascular AT. As expected, relative to lean rats (% body fat = 13.5 ± 0.7), obese rats (% body fat = 27.2 ± 0.8) were hyperlipidemic (total cholesterol 77.0 ± 2.1 vs. 101.0 ± 3.3 mg/dL), hyperleptinemic (5.3 ± 0.9 vs. 191.9 ± 59.9 pg/mL), and insulin-resistant (higher HOMA IR index [3.9 ± 0.8 vs. 25.2 ± 4.1]). Obese rats also exhibited increased expression of proinflammatory genes in perivascular, visceral, and brown ATs. L-NAME treatment produced a small but statistically significant decrease in percent body fat (24.6 ± 0.9 vs. 27.2 ± 0.8%) and HOMA IR index (16.9 ± 2.3 vs. 25.2 ± 4.1) in obese rats. Further, contrary to our hypothesis, we found that expression of inflammatory genes in all AT depots examined were generally unaltered with L-NAME treatment in both lean and obese rats. This was in contrast with the observation that L-NAME produced a significant upregulation of inflammatory and proatherogenic genes in the aorta. Collectively, these findings suggest that chronic NOS inhibition alters transcriptional regulation of proinflammatory genes to a greater extent in the aortic wall compared to its adjacent perivascular AT, or visceral white and subscapular brown AT depots.

Keywords: Inflammation; L‐NAME; obesity; vascular function

References

  1. Circ Res. 2009 Feb 27;104(4):541-9 - PubMed
  2. Curr Opin Lipidol. 2010 Jun;21(3):172-7 - PubMed
  3. Curr Diab Rep. 2009 Feb;9(1):26-32 - PubMed
  4. Am J Physiol Heart Circ Physiol. 2005 May;288(5):H2031-41 - PubMed
  5. Exp Physiol. 2013 Jan;98(1):337-47 - PubMed
  6. Arterioscler Thromb. 1994 May;14(5):753-9 - PubMed
  7. Nitric Oxide. 2010 Aug 1;23(1):42-50 - PubMed
  8. PLoS One. 2010 Jun 04;5(6):e10962 - PubMed
  9. Acta Physiol (Oxf). 2011 Sep;203(1):167-80 - PubMed
  10. Br J Nutr. 2011 Nov;106(9):1337-48 - PubMed
  11. Arterioscler Thromb Vasc Biol. 2009 May;29(5):781-6 - PubMed
  12. Br J Pharmacol. 2012 Feb;165(3):659-69 - PubMed
  13. Clin Endocrinol (Oxf). 2006 Apr;64(4):355-65 - PubMed
  14. Am J Physiol Heart Circ Physiol. 2003 Dec;285(6):H2430-6 - PubMed
  15. Jpn J Physiol. 1997 Oct;47(5):477-80 - PubMed
  16. Am J Physiol Heart Circ Physiol. 2003 Dec;285(6):H2524-30 - PubMed
  17. Circulation. 2001 Jul 24;104(4):448-54 - PubMed
  18. Am J Physiol Regul Integr Comp Physiol. 2013 Apr 1;304(7):R543-52 - PubMed
  19. Atherosclerosis. 2008 Apr;197(2):896-903 - PubMed
  20. Proc Natl Acad Sci U S A. 1987 Dec;84(24):9265-9 - PubMed
  21. J Clin Invest. 2003 Dec;112(12):1785-8 - PubMed
  22. Free Radic Biol Med. 2008 Jul 1;45(1):18-31 - PubMed
  23. Int J Obes Relat Metab Disord. 2002 Jun;26(6):754-64 - PubMed
  24. Int J Obes (Lond). 2008 Feb;32(2):268-74 - PubMed
  25. Annu Rev Pharmacol Toxicol. 1997;37:339-59 - PubMed
  26. Biochem J. 2013 Aug 15;454(1):1-11 - PubMed
  27. Am J Physiol Heart Circ Physiol. 2001 Dec;281(6):H2528-38 - PubMed
  28. Acta Physiol Scand. 2001 Sep;173(1):113-8 - PubMed
  29. Clin Sci (Lond). 2012 Jan;122(1):1-12 - PubMed
  30. J Hypertens. 2011 Aug;29(8):1515-27 - PubMed
  31. Exp Physiol. 2013 Nov;98(11):1576-84 - PubMed
  32. Vascul Pharmacol. 2010 Jan-Feb;52(1-2):27-36 - PubMed
  33. J Clin Invest. 2013 Jan;123(1):215-23 - PubMed
  34. Arterioscler Thromb Vasc Biol. 2010 Sep;30(9):1711-7 - PubMed
  35. Am J Physiol Heart Circ Physiol. 2010 Jun;298(6):H1889-901 - PubMed
  36. J Clin Invest. 1998 Feb 15;101(4):731-6 - PubMed
  37. Eur J Appl Physiol. 2014 Mar;114(3):531-44 - PubMed
  38. Nat Med. 2001 Oct;7(10):1138-43 - PubMed
  39. J Clin Invest. 2006 Jul;116(7):1793-801 - PubMed
  40. J Inflamm (Lond). 2012 Jul 19;9(1):28 - PubMed
  41. Diabetes. 2013 Jun;62(6):1783-90 - PubMed
  42. J Appl Physiol (1985). 2008 Jan;104(1):186-97 - PubMed
  43. Arterioscler Thromb Vasc Biol. 2011 Dec;31(12):2827-35 - PubMed
  44. Atherosclerosis. 2009 Jan;202(1):48-57 - PubMed
  45. Nature. 1987 Jun 11-17;327(6122):524-6 - PubMed
  46. Am J Physiol Heart Circ Physiol. 2011 Oct;301(4):H1425-37 - PubMed
  47. Circ Res. 2012 Oct 12;111(9):1176-89 - PubMed
  48. Circulation. 2003 Nov 18;108(20):2460-6 - PubMed
  49. J Appl Physiol (1985). 2012 Dec 15;113(12):1873-83 - PubMed

Publication Types

Grant support